{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T15:34:01Z","timestamp":1770824041393,"version":"3.50.1"},"reference-count":30,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2002,5,15]]},"abstract":"<jats:p>Molecular abnormalities caused by the hybrid Bcr-Abl gene are causally associated with the development and progression of Philadelphia chromosome\u2013positive (Ph+) chronic myelogenous leukemia (CML). Imatinib mesylate (STI571), a specific Bcr-Abl tyrosine-kinase signal-transduction inhibitor, has shown encouraging activity in phase I and II studies of CML. Here, we describe the use of imatinib mesylate to treat 75 patients in blast-phase CML (median age, 53 years; 65 with nonlymphoid and 10 with lymphoid blasts), and compare the results with those of a historical control group treated with standard cytarabine-based therapy. Imatinib mesylate was given as oral doses at 300 to 1000 mg per day and was the first salvage therapy for 47 patients. The objective response rate was 52% (39 of 75 patients: 16 had complete and 3 had partial hematologic response; 12 had hematologic improvement; 7 returned to second chronic phase; and 1 had a complete response in extramedullary blastic disease). Response rates were not different between nonlymphoid and lymphoid groups. The cytogenetic response rate was 16% (12 patients: 5 complete, 3 partial [Ph+ below 35%], and 4 minor [Ph+, 34% to 90%]). The estimated median overall survival was 6.5 months; the estimated 1-year survival was 22%. Response to therapy (landmark analysis at 8 weeks) was associated with survival prolongation. Compared with standard cytarabine combinations, imatinib mesylate therapy was less toxic and produced a higher response rate (55% versus 29%, P\u2009=\u2009.001), longer median survival (7 versus 4 months, P\u2009=\u2009.04), and lower 4-week induction mortality (4% versus 15%, P\u2009=\u2009.07). Imatinib mesylate is currently being tested in combination with other drugs to improve the prognosis for blast-phase CML.<\/jats:p>","DOI":"10.1182\/blood.v99.10.3547","type":"journal-article","created":{"date-parts":[[2002,10,1]],"date-time":"2002-10-01T21:48:18Z","timestamp":1033508898000},"page":"3547-3553","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":231,"title":["Imatinib mesylate (STI571) therapy for Philadelphia chromosome\u2013positive chronic myelogenous leukemia in blast phase"],"prefix":"10.1182","volume":"99","author":[{"given":"Hagop M.","family":"Kantarjian","sequence":"first","affiliation":[{"name":"From the Departments of Leukemia, Hematopathology, and Bioimmunotherapy, The University of Texas MD Anderson Cancer Center, Houston, TX, and Novartis Oncology, East Hanover, NJ."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia, Hematopathology, and Bioimmunotherapy, The University of Texas MD Anderson Cancer Center, Houston, TX, and Novartis Oncology, East Hanover, NJ."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"O'Brien","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia, Hematopathology, and Bioimmunotherapy, The University of Texas MD Anderson Cancer Center, Houston, TX, and Novartis Oncology, East Hanover, NJ."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis J.","family":"Giles","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia, Hematopathology, and Bioimmunotherapy, The University of Texas MD Anderson Cancer Center, Houston, TX, and Novartis Oncology, East Hanover, NJ."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maher","family":"Albitar","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia, Hematopathology, and Bioimmunotherapy, The University of Texas MD Anderson Cancer Center, Houston, TX, and Novartis Oncology, East Hanover, NJ."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Beth","family":"Rios","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia, Hematopathology, and Bioimmunotherapy, The University of Texas MD Anderson Cancer Center, Houston, TX, and Novartis Oncology, East Hanover, NJ."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianqin","family":"Shan","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia, Hematopathology, and Bioimmunotherapy, The University of Texas MD Anderson Cancer Center, Houston, TX, and Novartis Oncology, East Hanover, NJ."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Faderl","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia, Hematopathology, and Bioimmunotherapy, The University of Texas MD Anderson Cancer Center, Houston, TX, and Novartis Oncology, East Hanover, NJ."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia, Hematopathology, and Bioimmunotherapy, The University of Texas MD Anderson Cancer Center, Houston, TX, and Novartis Oncology, East Hanover, NJ."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah A.","family":"Thomas","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia, Hematopathology, and Bioimmunotherapy, The University of Texas MD Anderson Cancer Center, Houston, TX, and Novartis Oncology, East Hanover, NJ."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debra","family":"Resta","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia, Hematopathology, and Bioimmunotherapy, The University of Texas MD Anderson Cancer Center, Houston, TX, and Novartis Oncology, East Hanover, NJ."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moshe","family":"Talpaz","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia, Hematopathology, and Bioimmunotherapy, The University of Texas MD Anderson Cancer Center, Houston, TX, and Novartis Oncology, East Hanover, NJ."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2020021217501284300_B1","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1182\/blood.V82.3.691.691","article-title":"Chronic myelogenous leukemia: a concise update.","volume":"82","author":"Kantarjian","year":"1993","journal-title":"Blood."},{"key":"2020021217501284300_B2","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/blood.V87.8.3069.bloodjournal8783069","article-title":"Treatment of chronic myelogenous leukemia: current status and investigational options.","volume":"87","author":"Kantarjian","year":"1996","journal-title":"Blood."},{"key":"2020021217501284300_B3","doi-asserted-by":"crossref","first-page":"207","DOI":"10.7326\/0003-4819-131-3-199908030-00008","article-title":"Chronic myelogenous leukemia: biology and therapy.","volume":"131","author":"Faderl","year":"1999","journal-title":"Ann Intern Med."},{"key":"2020021217501284300_B4","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1126\/science.2406902","article-title":"Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome.","volume":"274","author":"Daley","year":"1990","journal-title":"Science."},{"key":"2020021217501284300_B5","doi-asserted-by":"crossref","first-page":"6649","DOI":"10.1073\/pnas.87.17.6649","article-title":"Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and bcr.","volume":"87","author":"Kelliher","year":"1990","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2020021217501284300_B6","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1002\/(SICI)1097-0142(19991215)86:12<2632::AID-CNCR7>3.0.CO;2-A","article-title":"Chronic myelogenous leukemia in nonlymphoid blastic phase. Analysis of the results of first salvage therapy with three different treatment approaches for 162 patients.","volume":"86","author":"Sacchi","year":"1999","journal-title":"Cancer."},{"key":"2020021217501284300_B7","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0002-9343(93)90122-6","article-title":"Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis.","volume":"94","author":"Derderian","year":"1993","journal-title":"Am J Med."},{"key":"2020021217501284300_B8","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1002\/1097-0142(20011115)92:10<2501::AID-CNCR1600>3.0.CO;2-N","article-title":"Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in blastic phase.","volume":"92","author":"Kantarjian","year":"2001","journal-title":"Cancer."},{"key":"2020021217501284300_B9","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1200\/JCO.2001.19.3.762","article-title":"Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia.","volume":"19","author":"Giles","year":"2001","journal-title":"J Clin Oncol."},{"key":"2020021217501284300_B10","first-page":"3696","article-title":"Biochemically directed therapy of leukemia with tiazofurin, a selective blocker of inosine 5\u2032-phosphate dehydrogenase activity.","volume":"49","author":"Tricot","year":"1989","journal-title":"Cancer Res."},{"key":"2020021217501284300_B11","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells.","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med."},{"key":"2020021217501284300_B12","first-page":"1661","article-title":"Selective inhibition of cell proliferation and BCR-ABL phophorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57184).","volume":"4","author":"Beran","year":"1998","journal-title":"Clin Cancer Res."},{"key":"2020021217501284300_B13","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med."},{"key":"2020021217501284300_B14","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the bcr-abl tyrosine kinase in chronic myeloid leukemia.","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med."},{"key":"2020021217501284300_B15","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.","volume":"346","author":"Kantarjian","year":"2002","journal-title":"New Engl J Med."},{"key":"2020021217501284300_B16","first-page":"469a","article-title":"A phase II study of STI 571 in adult patients with Philadelphia chromosome positive chronic myeloid leukemia in accelerated phase [abstract].","volume":"96","author":"Talpaz","year":"2000","journal-title":"Blood."},{"key":"2020021217501284300_B17","first-page":"503a","article-title":"A phase II study to determine the safety and anti-leukemic effects of imatinib mesylate in patients with Philadelphia chromosome positive chronic myeloid leukemia in myeloid blast crisis [abstract].","volume":"96","author":"Sawyers","year":"2000","journal-title":"Blood."},{"key":"2020021217501284300_B18","first-page":"828a","article-title":"A phase II study to determine the safety and anti-leukemic effects of imatinib mesylate in adult patients with Philadelphia chromosome positive acute leukemias [abstract].","volume":"96","author":"Ottman","year":"2000","journal-title":"Blood"},{"key":"2020021217501284300_B19","first-page":"218","volume-title":"In: Dacie JW, Andrews SM, eds. Practical Haematology.","author":"Dacie","year":"1968","edition":"4th ed."},{"key":"2020021217501284300_B20","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations.","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc."},{"key":"2020021217501284300_B21","first-page":"163","article-title":"Evaluations of survival data and two new rank order statistics arising in its consideration.","volume":"50","author":"Mantel","year":"1966","journal-title":"Cancer Chemother Rep."},{"key":"2020021217501284300_B22","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1200\/JCO.1983.1.11.710","article-title":"Analysis of survival by tumor response.","volume":"1","author":"Anderson","year":"1983","journal-title":"J Clin Oncol."},{"key":"2020021217501284300_B23","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life tables (with discussion).","volume":"34","author":"Cox","year":"1972","journal-title":"J Royal Stat Soc."},{"key":"2020021217501284300_B24","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1200\/JCO.20.3.656","article-title":"Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia.","volume":"20","author":"Giles","year":"2002","journal-title":"J Clin Oncol."},{"key":"2020021217501284300_B25","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1038\/sj.leu.2400796","article-title":"Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia.","volume":"11","author":"Kantarjian","year":"1997","journal-title":"Leukemia."},{"key":"2020021217501284300_B26","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood.V86.9.3322.bloodjournal8693322","article-title":"Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase.","volume":"86","author":"O'Brien","year":"1995","journal-title":"Blood."},{"key":"2020021217501284300_B27","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.1200\/JCO.2000.18.20.3513","article-title":"Homoharringtonine and low-dose cytarabine in the management of late chronic-phase myelogenous leukemia.","volume":"18","author":"Kantarjian","year":"2000","journal-title":"J Clin Oncol."},{"key":"2020021217501284300_B28","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1182\/blood.V97.5.1404","article-title":"Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR\/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia.","volume":"97","author":"Peters","year":"2001","journal-title":"Blood."},{"key":"2020021217501284300_B29","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1182\/blood.V97.11.3361","article-title":"Clinical and biological activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial.","volume":"97","author":"Karp","year":"2001","journal-title":"Blood."},{"key":"2020021217501284300_B30","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/sj.leu.2402104","article-title":"Co-treatment with As2O3 enhances selective cytotoxic effects on STI-571 against Bcr-Abl-positive acute leukemia cells.","volume":"15","author":"Porosnicu","year":"2001","journal-title":"Leukemia."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/99\/10\/3547\/1685107\/h81002003547.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/99\/10\/3547\/1685107\/h81002003547.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T06:15:17Z","timestamp":1733811317000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/99\/10\/3547\/107031\/Imatinib-mesylate-STI571-therapy-for-Philadelphia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,5,15]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2002,5,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.v99.10.3547","relation":{},"ISSN":["1528-0020","0006-4971"],"issn-type":[{"value":"1528-0020","type":"electronic"},{"value":"0006-4971","type":"print"}],"subject":[],"published":{"date-parts":[[2002,5,15]]}}}